Summary & Overview
HCPCS G9137: Non-Hodgkin's Lymphoma Disease Status, Relapsed/Refractory
HCPCS Level II code G9137 identifies an oncology service for assessing disease status in patients with Non-Hodgkin's lymphoma who have relapsed or are refractory to prior therapy, designated for use within a Medicare-approved demonstration project. The code matters nationally because it captures a focused clinical assessment tied to advanced-stage lymphoma management and demonstration-driven care pathways, which can affect documentation, program evaluation, and reimbursement processes in participating programs. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical context, typical sites of service, and which payers are relevant for coverage considerations. The publication outlines the policy and billing implications associated with demonstration-project-specific HCPCS reporting, highlights common modifier usage, and provides guidance on where to locate supporting documentation in medical records. It also summarizes what to expect in payer interactions when this code is used as part of demonstration or special-project reporting. Data not available in the input is noted where applicable, including detailed associated taxonomies, ICD-10 mappings, and line-item service settings beyond general outpatient oncology contexts.
Billing Code Overview
HCPCS Level II code G9137 denotes a service related to oncology disease status assessment for Non-Hodgkin's lymphoma, specified for relapsed/refractory disease and intended for use in a Medicare-approved demonstration project. The code describes evaluation of disease status rather than therapeutic treatment.
Service type: Oncology — disease status assessment
Typical site of service: Hospital outpatient departments, oncology clinics, and other outpatient settings involved in cancer disease assessment
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a prior diagnosis of non-Hodgkin's lymphoma presents to a specialized oncology clinic participating in a Medicare-approved demonstration project for relapsed/refractory disease management. The patient previously received first-line chemoimmunotherapy and now exhibits progressive lymphadenopathy, B symptoms, and rising lactate dehydrogenase. The oncology team performs a comprehensive disease-status assessment to determine eligibility for salvage regimens or clinical trial enrollment. The workflow includes chart review, recent imaging review (CT/PET), targeted physical exam, review of pathology reports and prior response, documentation of prior therapies and lines of treatment, and multidisciplinary tumor board discussion. Required documentation elements include disease status determination (relapsed vs refractory), date of relapse or progression, measurable disease sites, performance status, and planned next steps (salvage chemotherapy, targeted therapy, cellular therapy referral, or palliative measures). Typical interactions occur in an outpatient oncology clinic or an academic cancer center infusion/consult clinic with coordination of prior authorization and Medicare demonstration project reporting requirements.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | When the documentation supports substantially greater work or complexity for the disease-status assessment than typical for the service. |